Second doses of AstraZeneca vaccine are still on their way to South Africa

Early data shows the Oxford AstraZeneca vaccine offers only minimal protection against the new Covid-19 variant identified in South Africa last year. However, this will not prevent the rollout of the one million vaccines South Africa received last week. 

A study conducted by the University of Witwatersrand, which is not yet peer-reviewed, shows a “two-dose regimen of the vaccine provides minimal protection against mild-

 to moderate Covid-19 infection from the coronavirus variant first identified [in]  mid-November last year”.

However, the vaccine did show high efficacy against the original coronavirus variants in South Africa.

But “90% of all new infections in South Africa are from the more transmissible 501Y.V2, which were discovered last year,” said Shabir Madhi, chief investigator on the trial in South Africa, during a media briefing prompted by the announcement of the study. 

The department of health and a panel of experts briefed the media on Sunday evening.

Asking whether we should take the risk of not vaccinating high-risk groups, Madhi said, “It will be irresponsible to discard the [one] million vaccines that are available. We might want to reframe our target group for vaccination in the next few weeks.”

Where does it leave us?

  • Minister of Health Zweli Mkhize confirmed that the vaccination rollout for healthcare workers, which is due to start in the next few weeks, will proceed — but that it will be adjusted. 
  • Early data shows that the mutations in the virus seen in South Africa will allow ongoing transmission of the virus in vaccinated populations. 
  • But vaccines may continue to ease the toll on healthcare systems by preventing severe disease.
  • Research is already underway at the University of Oxford to produce a second generation of the AstraZeneca vaccine. 
  • The AstraZeneca vaccines will expire in April. 

The next shipment of 500 000 AstraZeneca doses is set to arrive in the country later this month.

Subscribe to the M&G

These are unprecedented times, and the role of media to tell and record the story of South Africa as it develops is more important than ever.

The Mail & Guardian is a proud news publisher with roots stretching back 35 years, and we’ve survived right from day one thanks to the support of readers who value fiercely independent journalism that is beholden to no-one. To help us continue for another 35 future years with the same proud values, please consider taking out a subscription.

Eunice Stoltz
Eunice Stoltz is a junior daily news reporter at the Mail & Guardian. She was previously a freelance journalist and a broadcaster at Maroela Media and Smile90.4FM.

Related stories


Subscribers only

Ithala fails to act against board chairperson over PPE scandal

Morar asked to settle with the state and pay back the profit he made on an irregular tender

Vodacom swindled out of more than R24m worth of iPhones

A former employee allegedly ran an intricate scam to steal 8700 phones from the cellular giant

More top stories

Investigate crimes in Tigray now, or risk a fragmented Ethiopia

For any investigation to be successful, evidence must be collected before it degrades

A Gauteng firm is using bioplastics to limit microplastics

Humans eat, drink and breathe in tens of thousands of micro- and nanoplastics, but research into the effects on health is limited

Mpumalanga, Western Cape don’t comply with threatened and protected species...

The provinces cite limited capacity and funds to implement the regulations

Meet Norman Chisale, Malawi’s richest bodyguard

Norman Chisale, the former Malawian president’s security chief, is struggling to account for his enormous wealth.

press releases

Loading latest Press Releases…